地麦角腈 | 59091-65-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 地麦角腈
• 英文名称: CM 29-712
• 英文别名: D-6-Methyl-8-cyanmethylisoergolin-1；6-Metyl-8α-cyanmethyl-ergolin-I；Delergotrile；(6-methyl-ergolin-8-yl)-acetonitrile；6-Methylergoline-8α-acetonitrile；8α-cyanomethyl-6-methylergoline；2-[(6aR,9R,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]acetonitrile
• CAS: 59091-65-5
• 化学式: C₁₇H₁₉N₃
• 分子量: 265.358
• InChiKey: LBMFWYCMCHRLBU-SGIREYDYSA-N

物化性质

• 沸点：
  500.9±40.0 °C(Predicted)
• 密度：
  1.179±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  42.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN
  申请人：Ackley Michael Andrew

  公开号：US20090318451A1

  公开（公告）日：2009-12-24

  The present invention relates to use of a compound of formula (I), (Ia), or (Ib): wherein A, B, Z, R 1 and R 2 have the meanings given in the specification, as a medicament for the treatment of a number of pain conditions, particularly chronic or nociceptive pain, in a mammal.

  本发明涉及使用式（I），（Ia）或（Ib）的化合物：其中A，B，Z，R1和R2具有规范中给定的含义，作为治疗哺乳动物的许多疼痛症状，特别是慢性或伤害性疼痛的药物。
• Process for the preparation of dihydrolysergic acid esters
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP0095091A2

  公开（公告）日：1983-11-30

  A process for the preparation of dihydrolysergic acid esters of the formula wherein R is alkyl of up to 3 carbon atoms and the substituent in the 8-position can be in the a- or β-position, comprising reacting the corresponding acid amide with an alcohol at temperatures of 20° to 55°C for 8 to 50 hours in the presence of an acid or an acidic ion exchange resin at a pH of 0-1.

  一种制备式中二氢麦角酸酯的工艺 式中 R 是最多 3 个碳原子的烷基，8 位上的取代基可以是 a 或 β 位上的取代基，包括在酸或酸性离子交换树脂存在下，在 20° 至 55°C 温度下，使相应的酸酰胺与醇在 pH 值为 0-1 的条件下反应 8 至 50 小时。
• Methods and devices for the treatment of ocular conditions
  申请人：deJuan Eugene

  公开号：US20060110428A1

  公开（公告）日：2006-05-25

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.
• METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS
  申请人：deJuan Eugene

  公开号：US20110159073A1

  公开（公告）日：2011-06-30

  Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.